Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome

Overview

Journal Semin Oncol

Specialty Oncology

Date 2011 Sep 28

PMID 21943668

Citations 29

Authors

Benjamin L Ebert

Affiliations

Soon will be listed here.

Abstract

The 5q-syndrome is a subtype of myelodysplastic syndrome (MDS) with a defined clinical phenotype associated with heterozygous deletions of chromosome 5q. While no genes have been identified that undergo recurrent homozygous inactivation, functional studies have revealed individual genes that contribute to the clinical phenotype of MDS through haplo-insufficient gene expression. Heterozygous loss of the RPS14 gene on 5q leads to activation of p53 in the erythroid lineage and the macrocytic anemia characteristic of the 5q-syndrome. The megakaryocytic and platelet phenotype of the 5q-syndrome has been attributed to heterozygous deletion of miR145 and miR146a. Murine models have implicated heterozygous loss of APC, EGR1, DIAPH1, and NPM1 in the pathophysiology of del(5q) MDS. These findings indicate that the phenotype of MDS patients with deletions of chromosome 5q is due to haplo-insufficiency of multiple genes.

Citing Articles

MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells.

Zhang H, Guo R, Li Z, Ma R, Xu S, Yin L Leukemia. 2024; 39(1):265-270.

PMID: 39438589 DOI: 10.1038/s41375-024-02447-9.

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.

Serrano G, Berastegui N, Diaz-Mazkiaran A, Garcia-Olloqui P, Rodriguez-Res C, Huerga-Dominguez S Nat Commun. 2024; 15(1):5272.

PMID: 38902243 PMC: 11189937. DOI: 10.1038/s41467-024-49529-x.

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.

Nishiguchi G, Mascibroda L, Young S, Caine E, Abdelhamed S, Kooijman J Nat Commun. 2024; 15(1):482.

PMID: 38228616 PMC: 10791743. DOI: 10.1038/s41467-024-44698-1.

Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.

Fuchs S, Stalmann U, Snoeren I, Bindels E, Schmitz S, Banjanin B Blood Adv. 2023; 8(3):766-779.

PMID: 38147624 PMC: 10847877. DOI: 10.1182/bloodadvances.2022008926.

A low carbohydrate diet high in fish oil and soy protein delays inflammation, hematopoietic stem cell depletion, and mortality in miR-146a knock-out mice.

Elisia I, Kowalski S, Yeung M, Wong J, Grants J, Karsan A Front Nutr. 2022; 9:1017347.

PMID: 36505238 PMC: 9729559. DOI: 10.3389/fnut.2022.1017347.

References

Zhao N, Stoffel A, Wang P, Eisenbart J, Espinosa 3rd R, Larson R . Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997; 94(13):6948-53. PMC: 21265. DOI: 10.1073/pnas.94.13.6948. View

Fairman J, Chumakov I, Chinault A, Nowell P, Nagarajan L . Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci U S A. 1995; 92(16):7406-10. PMC: 41348. DOI: 10.1073/pnas.92.16.7406. View

Valencia A, Cervera J, Such E, Sanz M, Sanz G . Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood. 2008; 112(3):918. DOI: 10.1182/blood-2008-05-159707. View

Teerenhovi L . Specificity of haematological indicators for '5q- syndrome' in patients with myelodysplastic syndromes. Eur J Haematol. 1987; 39(4):326-30. DOI: 10.1111/j.1600-0609.1987.tb00777.x. View

Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

Giagounidis A, Germing U, Aul C . Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006; 12(1):5-10. DOI: 10.1158/1078-0432.CCR-05-1437. View

Farrar J, Nater M, Caywood E, McDevitt M, Kowalski J, Takemoto C . Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008; 112(5):1582-92. PMC: 2518874. DOI: 10.1182/blood-2008-02-140012. View

Joslin J, Fernald A, Tennant T, Davis E, Kogan S, Anastasi J . Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007; 110(2):719-26. PMC: 1924479. DOI: 10.1182/blood-2007-01-068809. View

Ebert B, Pretz J, Bosco J, Chang C, Tamayo P, Galili N . Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008; 451(7176):335-9. PMC: 3771855. DOI: 10.1038/nature06494. View

10.

Starczynowski D, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A . Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2009; 16(1):49-58. DOI: 10.1038/nm.2054. View

11.

Barlow J, Drynan L, Hewett D, Holmes L, Lorenzo-Abalde S, Lane A . A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2009; 16(1):59-66. PMC: 2803774. DOI: 10.1038/nm.2063. View

12.

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

13.

Lane S, Sykes S, Al-Shahrour F, Shterental S, Paktinat M, Lo Celso C . The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010; 115(17):3489-97. PMC: 2867262. DOI: 10.1182/blood-2009-11-251728. View

14.

Boultwood J, Fidler C, Strickson A, Watkins F, Gama S, Kearney L . Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99(12):4638-41. DOI: 10.1182/blood.v99.12.4638. View

15.

Van Den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G . The 5q-anomaly. Cancer Genet Cytogenet. 1985; 17(3):189-255. DOI: 10.1016/0165-4608(85)90016-0. View

16.

Lehmann S, OKelly J, Raynaud S, Funk S, Sage E, Koeffler H . Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007; 21(9):1931-6. DOI: 10.1038/sj.leu.2404852. View

17.

Pellagatti A, Jadersten M, Forsblom A, Cattan H, Christensson B, Emanuelsson E . Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104(27):11406-11. PMC: 1892786. DOI: 10.1073/pnas.0610477104. View

18.

Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig T, Dianzani I . The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999; 21(2):169-75. DOI: 10.1038/5951. View

19.

Van Den Berghe H, Cassiman J, David G, Fryns J, Michaux J, SOKAL G . Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974; 251(5474):437-8. DOI: 10.1038/251437a0. View

20.

Gazda H, Grabowska A, Merida-Long L, Latawiec E, Schneider H, Lipton J . Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006; 79(6):1110-8. PMC: 1698708. DOI: 10.1086/510020. View